eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026 LOS ANGELES, CA / ACCESS Newswire/ March 25, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar on Tuesday, March 31, 2026 at 5:30 PM Eastern Time to discuss its results for the fourth quarter and full year 2025. A press release detailing these resu ...

Core Insights - eXoZymes Inc. has achieved a significant validation milestone for its cell-free biomanufacturing platform through a successful pilot scale run conducted by Cayman Chemical, demonstrating the technology's scalability and reliability [1][3] Group 1: Technology Validation - Cayman Chemical utilized eXoZymes' technology transfer package to scale up from a one-liter setup to a 100-liter pilot run, successfully managing real-world conditions that typically challenge enzyme-based processes [2] - The pilot run produced over 500 grams of pharma-grade N-trans-caffeoyltyramine (NCT) with a purity of 99.6%, showcasing a high level of efficiency with a 99% conversion rate of feedstock to end product [2][3] Group 2: Industry Impact - The successful pilot run is expected to facilitate partnerships for formulation development, product validation, and application-specific testing, allowing companies to move beyond feasibility studies [3][4] - eXoZymes aims to lead the market in biomanufacturing by offering advanced enzymes, termed "exozymes," which can replace traditional petrochemical processes and enhance sustainability [7][8]

Core Insights - eXoZymes is set to present a solution for scaling production of NCT, a naturally occurring small molecule with potential applications in nutraceuticals and pharmaceuticals, at the MISTA Symposium on March 18, 2026 [1] - The focus of the presentation will be on NCT's role in metabolic health and its relevance in the evolving landscape of food, supplements, and wellness solutions [1] - The company aims to leverage its proprietary exozyme platform to enable efficient production of NCT, addressing the historical limitations of its rarity in nature [1] Company Overview - eXoZymes Inc. was founded in 2019 and has developed a biomanufacturing platform that utilizes AI-enhanced enzymes, termed "exozymes," to produce valuable natural products sustainably [1] - Exozymes operate outside living cells, allowing for scalable production and replacing traditional toxic petrochemical processes [1] - The company does not intend to trademark the term "exozymes," viewing it as a new nomenclature for the next generation of biomanufacturing [1] Industry Context - The MISTA Symposium will gather leaders from the food, nutrition, and health industries to discuss scientific advances that support healthier aging and improved metabolic resilience [1] - NCT has gained attention for its potential metabolic benefits, which could open new opportunities in the nutraceutical, pharmaceutical, and specialty ingredient markets [1] - The advancements in cell-free enzyme engineering are expected to facilitate the scalable production of previously impractical molecules [1]

Company Overview - eXoZymes Inc. is a pioneer in AI-engineered enzymes that convert sustainable feedstock into essential chemicals, medicines, and biofuels [1][3] - Founded in 2019, the company has developed a platform that optimizes natural processes for chemical production, offering a sustainable alternative to traditional methods [2] Upcoming Events - eXoZymes plans to host a webinar on April 2, 2025, at 4:30 p.m. Eastern Time to discuss its fourth quarter and full year 2024 results [1] - The CEO, Michael Heltzen, will lead the call along with select management team members to review recent developments and ongoing initiatives [1] Technology and Innovation - The company's exozymes are advanced enzymes enhanced with AI and bioengineering, designed to operate outside of living cells in bioreactors [3] - Exozymes provide sustainable and scalable biosolutions, replacing toxic petrochemical processes and inefficient biochemical extraction [3][4] - This technology addresses the scaling bottleneck that has hindered commercial success in the synthetic biology sector, marking a transition to the exozymes era of biotechnology [4]